The Risk and Benefits of Ketamine in Psychedelic Therapy: What We Can Learn from Matthew Perry’s Story

A Story That Demands Honest Attention

Matthew Perry died in October 2023. Court documents published the following year confirmed the cause: a ketamine overdose. He had been receiving clinical ketamine infusions through licensed providers. He had also been obtaining the drug through illegal channels and, by the time he died, injecting it up to six times a day.

Perry was not someone who ignored his struggles. He had spent an estimated $9 million on substance abuse treatment over his lifetime. He turned his Malibu home into a sober living facility for men. He wrote openly about addiction in his memoir, “Friends, Lovers, and the Big Terrible Thing,” and described ketamine as “a big exhale” after first encountering it at a rehab facility in Switzerland. He was, by any measure, someone actively trying to get better.

That context matters. Perry’s death is not a straightforward cautionary tale about a reckless person making reckless choices. It is a more uncomfortable story about what happens when a powerful medicine, a history of addiction, insufficient clinical safeguards, and willing suppliers converge. Understanding that distinction is where the actual learning begins.

What Ketamine Actually Does (and Why It Matters)

Ketamine was developed in the 1960s as a surgical anesthetic. Its newer clinical role emerged from a 2006 NIH study showing that intravenous ketamine could relieve severe depression within hours. That speed is remarkable compared to conventional antidepressants, which typically require weeks to show any effect and do not work for a meaningful portion of patients.

The drug is thought to work by modulating glutamate, a neurotransmitter involved in synaptic plasticity. It also appears to stimulate the growth of new neural connections, which researchers believe may contribute to its antidepressant effects and its potential in addiction treatment. Perry’s own use reflected this: ketamine was being explored as a tool for his alcohol and opioid dependence, not just for depression.

In 2019, the FDA approved esketamine (Spravato), a nasal spray formulation, specifically for treatment-resistant depression. Off-label ketamine infusions had already been offered at clinics across the country for several years by that point. The landscape expanded quickly, and regulation did not always keep pace.

The Real Risks Are Specific, Not Vague

Perry’s autopsy found ketamine in his system at a level roughly consistent with surgical anesthesia doses, far above the carefully calibrated amounts used therapeutically for depression. The therapeutic IV dose is typically around 0.5 mg per kilogram of body weight. Perry’s blood level at death was estimated to be many times higher than what a standard clinical infusion would produce. The ketamine in his system could not have come from his most recent supervised infusion, which had occurred more than a week before his death. The half-life of the drug is three to four hours or less.

This distinction is not a minor technical point. It is the core of what went wrong. The drug that killed him was not the drug administered by a trained clinician in a monitored setting. It was the drug obtained outside that structure, injected by a personal assistant with no medical training, after other providers had already refused to increase his dosage.

The specific risks of unsupervised ketamine use are well documented. High doses can cause respiratory depression, particularly when combined with other sedatives. Perry’s toxicology also showed buprenorphine and two benzodiazepines in his system alongside the ketamine. Each of those substances is capable of causing respiratory failure independently. In combination, the risk multiplies substantially. He was also found face down in a pool, alone. Sedation and disorientation at high doses make water, traffic, and other environmental hazards genuinely lethal.

Chronic unsupervised use carries a separate set of concerns: ketamine bladder syndrome, cognitive impairment, cardiovascular stress, and, as Perry’s case illustrates, a real potential for dependence in individuals with pre-existing addiction histories.

Why Supervised Clinical Use Is a Fundamentally Different Thing

None of the above means ketamine therapy itself is unsafe. The distinction between supervised clinical use and unsupervised use is not a legal technicality. It is the practical difference between a medication that helps and a substance that kills.

In a properly run clinical setting, dosage is calibrated to the individual. Vital signs are monitored throughout. The patient is not left alone. Access to additional doses is controlled. There is no mechanism by which someone walks out of a well-run ketamine clinic and injects themselves six times in a day.

What Perry encountered instead was a system where licensed physicians were later charged with illegal distribution, where his live-in assistant was administering injections without any medical training, and where, as revealed in court documents, suppliers openly discussed exploiting him financially. Five people were ultimately charged in connection with his death, including two doctors.

The proliferation of ketamine clinics across the country has been largely positive in terms of access, but uneven in terms of quality. Some operate with rigorous screening, integration support, and follow-up care. Others do not. The FDA approval of ketamine as an anesthetic means any physician can technically prescribe it off-label for psychiatric purposes, with limited mandatory oversight of how that is done.

Integration Is Not Optional

Harm reduction in psychedelic and ketamine therapy is not only about what happens during the session itself. What happens before and after carries equal weight.

Before treatment, a thorough intake process allows a clinician to understand the patient’s mental health history, addiction history, current medications, and psychological readiness. For someone with Perry’s background, that screening process should have raised specific flags about supervision requirements and the appropriateness of at-home use.

After treatment, integration work helps patients process what emerged during the experience and carry it meaningfully into their daily lives. This is where the shift from a pharmacological event to a therapeutic one actually happens. Without it, the window of neuroplasticity that ketamine opens may close without being used constructively.

Integration is also where dependency patterns can be caught early. A clinician who sees a patient regularly after sessions, asks honest questions, and monitors for signs of escalating use is in a position to intervene. That structure was absent in Perry’s case for a significant portion of his ketamine use.

What This Means for Anyone Considering Ketamine Therapy

Perry’s story is not a reason to reject ketamine therapy. The clinical evidence for its use in treatment-resistant depression, PTSD, and addiction is genuine and continues to grow. For people who have not found relief through conventional treatments, it represents a real option worth serious consideration.

What it does require is honesty about the conditions under which it can be used safely. Those conditions include a vetted provider with appropriate training, a thorough intake process that does not skip addiction history, a monitored session environment, preparation and integration support, and continuity of care that extends beyond the infusion itself.

It also requires recognizing that not every person is a good candidate for every protocol. At-home ketamine use, lozenges sent through the mail, and sessions without ongoing clinical oversight are not equivalent to supervised infusion therapy, regardless of how they are marketed. For individuals with complex mental health histories or addiction backgrounds, the gap in safety between those two approaches is wide.

Perry’s death was a failure of structure, not of the medicine itself. The lesson is not fear. It is rigor.